During the past decade, Shantou Central Hospital conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Shantou Central Hospital" #1 sponsor was "Guangdong Provincial People's Hospital" with 1 trials, followed by "Guangdong Raynovent Biotech Co., Ltd" with 1 trials sponsored, "Herui Yao" with 1 trials sponsored, "Jiangsu HengRui Medicine Co., Ltd." with 1 trials sponsored and "Lepu Medical Technology (Beijing) Co., Ltd." with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Shantou Central Hospital" #1 collaborator was "Affiliated Cancer Hospital & Institute of Guangzhou Medical University" with 1 trials as a collaborator, "First Affiliated Hospital of Shantou University Medical College" with 1 trials as a collaborator, "First Affiliated Hospital, Sun Yat-Sen University" with 1 trials as a collaborator, "Jiangsu HengRui Medicine Co., Ltd." with 1 trials as a collaborator and "Shantou Central Hospital" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Shantou Central Hospital" are "Metastatic Breast Cancer" (2 trials), "Breast Cancer" (1 trials), "Coronary Heart Disease" (1 trials), "Esophageal Cancer" (1 trials) and "Esophagus Cancer" (1 trials). Many other conditions were trialed in "Shantou Central Hospital" in a lesser frequency.

Most popular intervention types in "Shantou Central Hospital" are "Drug" (6 trials), "Other" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Bridging thrombolysis followed by ECR" (1 trials), "Capecitabine Oral Product" (1 trials), "Direct endovascular clot retrieval" (1 trials), "Dual anti-platelet therapy" (1 trials) and "Fulvestrant" (1 trials). Other intervention names were less common.

The vast majority of trials in "Shantou Central Hospital" are 8 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Shantou Central Hospital". 2 are not yet recruiting, 4 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Shantou Central Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Shantou Central Hospital, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 3 trials that are defined as “Not Applicable".